Breaking News, Collaborations & Alliances

Celldex Therapeutics, Roche Form Pact

Collaboration will evaluate the combination of varlilumab and MPDL3280A

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Celldex Therapeutics, Inc. has entered into a clinical trial collaboration with Roche to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex’s CD27 targeting investigational antibody, and MPDL3280A (anti-PDL1), Roche’s investigational cancer immunotherapy in a Phase 1/2 study in renal cell carcinoma. Varlilumab and MPDL3280A are part of a new class of investigational medicines known as cancer immunotherapies that are designed to harness the body&#8217...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters